Free Articles
Free to read — no membership required.
I Have APOE4. What Do I Do Now?
Written for someone who has just received an APOE4 result and does not yet know what it means — what the genotype does, what it does not, and the actions that have evidence behind them.
What APOE4 Means: A Practical Guide for Patients
What carrying one or two copies of APOE ε4 means for your brain, your risk, and the decisions in front of you — in plain language.
APOE 2, 3, and 4: What the Three Versions of This Gene Actually Do
Three versions of one gene, separated by two amino acids — and why that small difference sends Alzheimer’s risk in three different directions.
APOE ε4 Risk Is Not the Same in Every Population
The widely quoted risk figures come almost entirely from people of European ancestry. How much the numbers change elsewhere, and the haplotype explanation for why.
DHA and Brain Health: A Guide for APOE ε4 Carriers
Timing and molecular form both matter. What the DHA trials show for carriers before symptoms begin, and what they show after.
APOE ε4 or ApoE4? A Clinician’s Guide to Correct Nomenclature
Gene, allele, protein isoform, and search term are four different things. A short reference for using each correctly in writing and in clinic.
Stem Cells, Exosomes, and Peptides for Alzheimer’s Disease: What the Evidence Shows
A clinical review of regenerative therapies marketed to APOE ε4 carriers — what randomized evidence actually supports, and where it doesn’t.
The End of Alzheimer’s Program: A Neurologist’s Review
A board-certified neurologist and APOE ε4 carrier reviews Dale Bredesen’s bestselling protocol — what the evidence supports, and where it overclaims.
No More Sleepless Nights: A Neurologist’s Review
A physician’s review of a popular sleep program, and what the evidence actually says about sleep and APOE ε4 risk.
Why Some Scientists Question the Amyloid Hypothesis
Why the leading theory of Alzheimer’s disease is being challenged — and why it doesn’t change what APOE ε4 carriers should do.
Alzheimer’s Treatments and Emerging Therapies: A Guide for APOE ε4 Carriers
Current FDA-approved therapies, what’s in clinical trials, and what APOE ε4 status means for treatment candidacy.
Navigating Pre-Death Grief: Managing the Emotional Toll of Dementia Caregiving
The grief that begins long before the death does — why it is so often unrecognized, and what helps caregivers carry it.
Key Considerations After a Dementia Diagnosis in APOE ε4 Carriers
The decisions that matter most in the first months after a diagnosis, and the ones that can safely wait.
Who Helps After a Dementia Diagnosis? Building Your Care Team
Who belongs on the care team after a dementia diagnosis — and how to actually find a geriatric psychiatrist or social worker.
Intermittent Fasting: A Patient Guide
What intermittent fasting has been shown to do for brain aging, what remains mechanistic only, and who should not attempt it.
APOE ε4 Carriers and Meat
Dietary meat intake and cognitive outcomes in APOE ε4 carriers, and what the observational data can and cannot establish.
Member-Only Articles
Full clinical reviews and evidence tables. Become a member to unlock the complete library.
-
DHA Supplementation in APOE ε4 Carriers: A Stage-Dependent Clinical Framework
DHA supplementation in APOE ε4 carriers is stage-dependent. High-dose DHA (≥1–2 g/day) initiated before cognitive decline carries the…
-
Distinguishing iNPH from Alzheimer Disease: Key Imaging Differences
Distinguishing iNPH from Alzheimer Disease: Key Imaging Differences Neuroimaging · Clinical Differentiation · 2025 Distinguishing iNPH from Alzheimer…
-
Non-Alzheimer’s Dementia: Normal Pressure Hydrocephalus
Normal Pressure Hydrocephalus: A Treatable Cause of Dementia-Like Symptoms Evidence-Based Clinical Review · 2025–2026 Normal Pressure Hydrocephalus: The…
-
The Skin-Brain Axis: Dermatological Conditions and Dementia Risk
The Skin-Brain Axis: Dermatological Conditions and Dementia Risk — APOE4 Insights Neurology · Dermatology · Biomarkers The Skin-Brain…
-
Drug Therapies for Alzheimer’s-Type Dementia
An overview of currently approved pharmacotherapy for Alzheimer’s disease — including the anti-amyloid monoclonal antibodies lecanemab and donanemab…
-
Proactive Diagnostic Evaluation in the APOE ε3/ε4 Heterozygote: A Framework for Midlife Risk Stratification
Evidence-Based Clinical Review Proactive Diagnostic Evaluation in the APOE ε3/ε4 Heterozygote: A Framework for Midlife Risk Stratification A…
-
Amyloid PET Imaging: Mechanism and Clinical Utility in Cognitive Complaints
Amyloid PET Imaging: Mechanism and Clinical Utility in Cognitive Complaints APOE4 Insights · Review · May 2026 Mechanism…
-
APOE ε4 and Cognitive Decline: A Physician Clinical Reference
A structured clinical reference on APOE ε4 and cognitive trajectory: genotype-stratified risk estimates, mechanisms of ε4-associated neurodegeneration, and…
-
Clearing Amyloid and Tau in APOE ε4–Positive Individuals: Evidence-Based Strategies
Carrying the APOE4 allele is the strongest known genetic risk factor for late-onset Alzheimer’s disease (AD). Research published…
